King of Prussia, Pennsylvania – October 31, 2025 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing next-generation siRNA-based gene-silencing therapeutics, announced the appointment of Mr. David H. Deming as Lead Independent Director of its Board of Directors. Mr. Deming, a seasoned investment banking and asset management professional with over 30 years of experience, including 27 years with J.P. Morgan, brings strategic governance expertise that will enhance Phio’s corporate oversight as it advances its INTASYL® gene-silencing platform toward clinical and commercial milestones. His appointment signals Phio’s continued commitment to strong corporate governance, compliance, and long-term biopharma innovation.
Science Significance
Phio’s proprietary INTASYL® technology represents a cutting-edge gene-silencing platform that enhances immune cell functionality to selectively target and destroy cancer cells. Its lead program, PH-762, silences the PD-1 gene, a key immune checkpoint inhibitor implicated in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The ongoing Phase 1b clinical trial (NCT#06014086) evaluates PH-762’s potential as a non-surgical therapeutic for skin cancers, offering a new paradigm in immuno-oncology. The company’s scientific strategy emphasizes precision modulation of immune pathways, positioning INTASYL® among the next generation of RNA-based immunotherapies aimed at achieving deeper tumor control with improved tolerability.
Regulatory Significance
With the appointment of Mr. Deming, Phio strengthens the regulatory and governance structure guiding its clinical and preclinical programs. His extensive background in healthcare investment and corporate board leadership supports regulatory accountability and transparent reporting practices — essential components of Good Clinical Practice (GCP) and Good Corporate Governance in a publicly listed biopharma company. As Phio progresses its INTASYL® programs through FDA-monitored clinical development, this enhanced leadership oversight ensures compliance continuity, ethical data management, and readiness for regulatory submissions across its oncology pipeline. The move further demonstrates Phio’s alignment with cGxP principles — embedding quality, accountability, and traceability at every development stage.
Business Significance
Advertisement
Mr. Deming’s appointment reinforces Phio Pharmaceuticals’ strategic governance and investor confidence at a critical juncture of clinical expansion. His three decades of financial and healthcare sector expertise will help guide corporate financing strategies, strategic partnerships, and risk management frameworks aligned with biopharma industry standards. Phio’s leadership evolution supports a sustainable business model grounded in scientific integrity and regulatory excellence, strengthening its position within the competitive RNA-therapeutics market. As the company advances PH-762 and additional INTASYL® assets, robust board oversight ensures fiscal discipline, quality system resilience, and long-term growth stability.
Patients’ Significance
For patients with advanced or inoperable skin cancers, Phio’s PH-762 gene-silencing approach offers new hope for non-surgical and immune-enhancing therapies. By silencing PD-1 expression directly within tumor microenvironments, the treatment aims to boost the immune system’s ability to destroy cancer cells, potentially reducing the need for invasive procedures. This patient-centric innovation reflects Phio’s broader mission to translate RNA-based science into safer, more accessible cancer therapeutics. The company’s governance enhancements ensure that patient safety, ethical trial conduct, and data reliability remain central to every stage of product development.
Policy Significance
Phio’s appointment of an independent director with deep biopharma financial expertise aligns with emerging policy and governance trends that emphasize board independence, risk mitigation, and ethical oversight in the life sciences sector. Regulatory bodies such as the SEC and FDA continue to reinforce corporate governance as integral to maintaining GxP compliance, especially in companies handling advanced biological and genetic technologies. By integrating leadership accountability into its governance framework, Phio exemplifies the policy shift toward transparency, quality-driven oversight, and corporate responsibility that defines modern biopharma operations..
The appointment of David H. Deming as Lead Independent Director marks a significant step in Phio Pharmaceuticals’ evolution as a compliance-focused, innovation-driven biopharma company. His expertise in healthcare investment and governance enhances Phio’s capacity to manage both scientific advancement and regulatory obligations with precision and integrity. As Phio continues to expand its INTASYL® platform and advance PH-762 through clinical development, this strengthened leadership foundation underscores the company’s unwavering commitment to quality, compliance, and transformational oncology therapeutics — hallmarks of a modern cGxP-aligned biopharmaceutical enterprise.
Source : Phio Pharmaceuticals Corp. press release
